Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167192 | 0.87 | CREBBP (0.35) | CREBBPKMT2AALDH1A1KDM4E | |
| SCHEMBL5165682 | 0.86 | CREBBP (0.35) | CREBBPKMT2A | |
| SCHEMBL5168360 | 0.85 | RAB9A (0.36) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL5166413 | 0.84 | CREBBP (0.37) | CREBBPKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL5167270 | 0.83 | MEN1 (0.36) | CREBBPKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL5166910 | 0.82 | CREBBP (0.42) | CREBBPKMT2A | |
| SCHEMBL5168400 | 0.82 | PKM (0.36) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL5168909 | 0.81 | CREBBP (0.45) | CREBBPKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL5164581 | 0.80 | CREBBP (0.42) | CREBBPKMT2AALDH1A1KDM4E | |
| SCHEMBL5167375 | 0.79 | KMT2A (0.44) | CREBBPKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1326613-B2 | USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1326613-B1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | CREBBP 1065/4885KMT2A 2977/4885MEN1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.